Dexamethasone Azathioprine Pulse therapy — Competitive Intelligence Brief

Dexamethasone Azathioprine Pulse therapy (Dexamethasone Azathioprine Pulse therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy. Area: Immunology / Rheumatology.

marketed Immunosuppressive combination therapy Glucocorticoid receptor (dexamethasone); inosine monophosphate dehydrogenase (azathioprine) Immunology / Rheumatology Small molecule

Target snapshot

Dexamethasone Azathioprine Pulse therapy (Dexamethasone Azathioprine Pulse therapy) — Jinnah Postgraduate Medical Centre. This combination therapy uses dexamethasone (a corticosteroid) to suppress inflammation and azathioprine (an immunosuppressant) to inhibit T-cell proliferation, administered in pulse doses for rapid immune modulation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dexamethasone Azathioprine Pulse therapy TARGET	Dexamethasone Azathioprine Pulse therapy	Jinnah Postgraduate Medical Centre	marketed	Immunosuppressive combination therapy	Glucocorticoid receptor (dexamethasone); inosine monophosphate dehydrogenase (azathioprine)
Everolimus+Tacrolimus+Prednisone	Everolimus+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	mTOR (everolimus), calcineurin (tacrolimus), glucocorticoid receptor (prednisone)
ATG/PTCy	ATG/PTCy	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Immunosuppressive combination therapy
CsA+MMF+CS	CsA+MMF+CS	Pfizer	marketed	Immunosuppressive combination therapy	Calcineurin (CsA); IMPDH type II (MMF); glucocorticoid receptor (CS)
Kidney transplant maintenance immunosuppression	Kidney transplant maintenance immunosuppression	Imperial College Healthcare NHS Trust	marketed	Immunosuppressive combination therapy
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
Mycophenolate+Tacrolimus+Prednisone	Mycophenolate+Tacrolimus+Prednisone	Fundação Pró Rim	marketed	Immunosuppressive combination therapy	T-cell proliferation and activation (multiple targets: IMPDH, calcineurin, glucocorticoid receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy class)

1. University Hospital, Brest · 2 drugs in this class
2. Pfizer · 2 drugs in this class
3. Fundação Pró Rim · 2 drugs in this class
4. Haukeland University Hospital · 1 drug in this class
5. Imperial College Healthcare NHS Trust · 1 drug in this class
6. Jinnah Postgraduate Medical Centre · 1 drug in this class
7. Novartis · 1 drug in this class
8. Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. Swiss Cancer Institute · 1 drug in this class
10. University Hospital Freiburg · 1 drug in this class